Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
eflornithine
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Orbus Therap
Drug class:
Ornithine decarboxylase inhibitor
Related drugs:
‹
eflornithine/sulindac (1)
SBP-101 (1)
eflornithine/sulindac (1)
SBP-101 (1)
›
Associations
News
Trials
Filter by
Latest
8ms
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1, N=66, Recruiting, Orbus Therapeutics, Inc. | Phase classification: P1b --> P1
8 months ago
Phase classification
|
IDH wild-type
|
temozolomide • eflornithine
over1year
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1b, N=60, Recruiting, Orbus Therapeutics, Inc.
over 1 year ago
New P1 trial
|
IDH wild-type
|
temozolomide • eflornithine
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login